Fabrication of nanoadjuvant with poly-σ- caprolactone (PCL) for developing a single-shot vaccine providing prolonged immunity

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 937-950

  Prashant, Chandravilas Keshvan ^a   Bhat, Madhusudan ^a   Srivastava Kumar, Sandeep ^a   Saxena, Ankit ^a   Kumar, Manoj ^a   Singh, Amar ^a   Samim, Mohammed ^a   Ahmad, Farhan Jalees ^a   Dinda, Amit Kumar ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Adjuvant; Antigen cross presentation; Poly caprolactone nanoparticles; Tetanus toxoid; Vaccine

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; POLYCAPROLACTONE; TETANUS TOXOID; CAPROLACTONE; HEXANOIC ACID DERIVATIVE; IMMUNOLOGICAL ADJUVANT; LACTONE; NANOPARTICLE; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; DRUG FORMULATION; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVAPORATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; MACROPHAGE; MOUSE; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; POLARIZATION; TH1 CELL; TH2 CELL; ZETA POTENTIAL; ANIMAL; CELL LINE; CHEMISTRY; FEMALE; IMMUNOLOGY; NANOMEDICINE; NANOTECHNOLOGY; T LYMPHOCYTE SUBPOPULATION; ULTRASTRUCTURE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; CAPROATES; CELL LINE; FEMALE; HUMANS; LACTONES; MACROPHAGES; MICE; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; T-LYMPHOCYTE SUBSETS; TETANUS TOXOID; VACCINES;

EID: 84896853132     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S55892     Document Type: Article

References (44)

1. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-173.
2. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557-1569.
3. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164(12): 6166-6173.
4. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity. 2005:23(4):344-346.
5. Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A. 2012;109(4):1080-1085.
6. Li N, Peng LH, Chen X, Nakagawa S, Gao JQ. Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo. Int J Nanomedicine. 2011;6:3241-3250.
7. Yue H, Wei W, Fan B, et al. The orchestration of cellular and humoral responses is facilitated by divergent intracellular antigen trafficking in nanoparticle-based therapeutic vaccine. Pharmacol Res. 2012;65(2):189-197.
8. Gupta NK, Tomar P, Sharma V, Dixit VK. Development and characterization of chitosan coated poly-(σ-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine. 2011;29(48):9026-9037.
9. Jewell CM, López SC, Irvine DJ. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc Natl Acad Sci U S A. 2011;108(38):15745-15750.
10. Petersen LK, Ramer-Tait AE, Broderick SR, et al. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. Biomaterials. 2011;32(28): 6815-6822.
11. Uto T, Akagi T, Yoshinaga K, Toyama M, Akashi M, Baba M. The induction of innate and adaptive immunity by biodegradable poly(γ- glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomaterials. 2011;32(22):5206-5212.
12. Han R, Zhu J, Yang X, Xu H. Surface modification of poly(D,L- lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells. J Biomed Mater Res A. 2011;96(1):142-149.
13. Da Costa Martins R, Gamazo C, Sánchez-Martínez M, Barberán M, Peñuelas I, Irache JM. Conjunctival vaccination against Brucella ovis in mice with mannosylated nanoparticles. J Control Release. 2012;162(3): 553-560.
14. Wang T, Jiang H, Zhao Q, Wang S, Zou M, Cheng G. Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: effect of silica architecture on immunological properties. Int J Pharm. 2012;436(1-2):351-358.
15. Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine. 2010;6(4):523-529.
16. Caputo A, Castaldello A, Brocca-Cofano E, et al. Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. Vaccine. 2009;27(27):3605-3615.
17. Burgdorf S, Kurts C. Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol. 2008;20(1):89-95.
18. Stills HF Jr. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J. 2005;46(3):280-293.
19. Berzofsky JA, Ahlers JD, Janik J, et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest. 2004;114(4): 450-462.
20. Ma W, Chen M, Kaushal S, et al. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine. 2012;7:1475-1487.
21. Keijzer C, Slütter B, van der Zee R, Jiskoot W, van Eden W, Broere F. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS One. 2011;6(11):e26684.
22. Sneh-Edri H, Likhtenshtein D, Stepensky D. Intracellular targeting of PLGA nanoparticles encapsulating antigenic peptide to the endoplasmic reticulum of dendritic cells and its effect on antigen cross-presentation in vitro. Mol Pharm. 2011;8(4):1266-1275.
23. Chen J, Li Z, Huang H, et al. Improved antigen cross-presentation by polyethyleneimine-based nanoparticles. Int J Nanomedicine. 2011;6: 77-84.
24. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr Opin Microbiol. 2010;13(1):106-112.
25. Gutierro I, Hernández RM, Igartua M, Gascón AR, Pedraz JL. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine. 2002;21(1-2):67-77.
26. Cohen JA, Beaudette TT, Tseng WW, et al. T-cell activation by antigen- loaded pH-sensitive hydrogel particles in vivo: the effect of particle size. Bioconjug Chem. 2009;20(1):111-119.
27. Cruz LJ, Tacken PJ, Fokkink R, et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release. 2010;144(2):118-126.
28. Schliehe C, Redaelli C, Engelhardt S, et al. CD8- dendritic cells and macrophages cross-present poly(D,L-lactate-co-glycolate) acid microsphere-encapsulated antigen in vivo. J Immunol. 2011;187(5): 2112-2121.
29. Wilson JT, Keller S, Manganiello MJ, et al. pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano. 2013;7(5):3912-3925.
30. Patterson DP, Rynda-Apple A, Harmsen AL, Harmsen AG, Douglas T. Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. ACS Nano. 2013;7(4):3036-3044.
31. Gamvrellis A, Gloster S, Jefferies M, et al. Characterisation of local immune responses induced by a novel nano-particle based carrier-adjuvant in sheep. Vet Immunol Immunopathol. 2013;155(1-2): 21-29.
32. Lugade AA, Bharali DJ, Pradhan V, Elkin G, Mousa SA, Thanavala Y. Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity. Nanomedicine. 2013;9(7):923-934.
33. Mahony D, Cavallaro AS, Stahr F, Mahony TJ, Qiao SZ, Mitter N. Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice. Small. 2013;9(18):3138-3146.
34. Manish M, Rahi A, Kaur M, Bhatnagar R, Singh S. A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge. PLoS One. 2013;8(4): e61885.
35. Li N, Peng LH, Chen X, et al. Antigen-loaded nanocarriers enhance the migration of stimulated Langerhans cells to draining lymph nodes and induce effective transcutaneous immunization. Nanomedicine. Epub June 7, 2013.
36. Herrera OB, Golshayan D, Tibbott R, et al. A novel pathway of alloantigen presentation by dendritic cells. J Immunol. 2004;173(8): 4828-4837.
37. Rai AK, Thakur CP, Singh A, et al. Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis. PLoS One. 2012;7(2):e31551.
38. Woodruff MA, Hutmacher DW. The return of a forgotten polymer: polycaprolactone in the 21st century. Prog Polym Sci. 2010;35(10): 1217-1256.
39. Yue H, Wei W, Yue Z, et al. Particle size affects the cellular response in macrophages. Eur J Pharm Sci. 2010;41(5):650-657.
40. Lucarelli M, Gatti AM, Savarino G, et al. Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles. Eur Cytokine Netw. 2004;15(4):339-346.
41. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010;9(9):1095-1107.
42. Xiang SD, Scholzen A, Minigo G, et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods. 2006:40(1):1-9.
43. Mohanan D, Slütter B, Henriksen-Lacey M, et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release. 2010;147(3):342-349.
44. Shen H, Ackerman AL, Cody V, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous anti- gens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1):78-88.